NPM1 MUTATION
Clinical trials for NPM1 MUTATION explained in plain language.
Never miss a new study
Get alerted when new NPM1 MUTATION trials appear
Sign up with your email to follow new studies for NPM1 MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for Hard-to-Treat leukemia: drug combo trial launches
Disease control Recruiting nowThis early-stage study tests a new drug called ziftomenib combined with standard treatments for people with a type of acute myeloid leukemia (AML) that has come back or not responded to therapy. The main goal is to check safety and find the best dose. About 171 adults with specif…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 26, 2026 04:36 UTC
-
New drug combo aims to keep leukemia in remission after transplant
Disease control Recruiting nowThis study tests whether menin inhibitors can help prevent leukemia from returning after a stem cell transplant. About 20 adults with certain genetic types of acute leukemia will take these drugs as part of their regular care. Researchers will track how many patients stay cancer-…
Matched conditions: NPM1 MUTATION
Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated May 26, 2026 04:31 UTC
-
New combo therapy targets tough leukemia gene mutations
Disease control Recruiting nowThis early-stage study tests an experimental drug called ziftomenib added to usual treatments for acute myeloid leukemia (AML) in people with specific gene changes (NPM1 mutation or KMT2A rearrangement). About 420 adults with newly diagnosed or returning AML will receive ziftomen…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Kura Oncology, Inc. • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug hopes to keep leukemia away after transplant
Disease control Recruiting nowThis early-phase study tests an experimental drug called ziftomenib in adults with acute myeloid leukemia (AML) who have had a stem cell transplant. The goal is to find a safe dose and see if the drug can help prevent the cancer from coming back. About 22 participants will take t…
Matched conditions: NPM1 MUTATION
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 14, 2026 12:02 UTC